Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05585632 · ClinicalTrials.gov registry record · Phase 1
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 392
- Enrollment target
NCT05585632 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 392 participants.
The verdict
NCT05585632, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 392 participants
- Enrollment target
Study Summary
The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older participants.
Interventions
- BIOLOGICAL mRNA-1345
- BIOLOGICAL mRNA-1010
- BIOLOGICAL mRNA-1273.214
- BIOLOGICAL mRNA-1045
- BIOLOGICAL mRNA-1230
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2022-10-14 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05585632
The ClinicalTrials.gov registry entry for NCT05585632 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 392 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mRNA-1345 is the first listed.
NCT05585632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05585632 about?
NCT05585632 is a clinical study titled "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old". The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older particip...
What is the current status of trial NCT05585632?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 392 participants. The study started on 2022-10-14. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT05585632?
The interventions under investigation include: mRNA-1345 (BIOLOGICAL), mRNA-1010 (BIOLOGICAL), mRNA-1273.214 (BIOLOGICAL), mRNA-1045 (BIOLOGICAL), mRNA-1230 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05585632?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.